- Home
- FONR vs ZNTL Comparison
FONR vs ZNTL Comparison
Compare FONR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FONR
- ZNTL
- Stock Information
- Founded
- FONR 1978
- ZNTL 2014
- Country
- FONR United States
- ZNTL United States
- Employees
- FONR N/A
- ZNTL N/A
- Industry
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- FONR Health Care
- ZNTL Health Care
- Exchange
- FONR Nasdaq
- ZNTL Nasdaq
- Market Cap
- FONR 100.6M
- ZNTL 105.8M
- IPO Year
- FONR 1987
- ZNTL 2020
- Fundamental
- Price
- FONR $15.30
- ZNTL $1.47
- Analyst Decision
- FONR
- ZNTL Buy
- Analyst Count
- FONR 0
- ZNTL 6
- Target Price
- FONR N/A
- ZNTL $6.53
- AVG Volume (30 Days)
- FONR 9.9K
- ZNTL 729.8K
- Earning Date
- FONR 09-12-2025
- ZNTL 11-11-2025
- Dividend Yield
- FONR N/A
- ZNTL N/A
- EPS Growth
- FONR N/A
- ZNTL N/A
- EPS
- FONR 1.21
- ZNTL N/A
- Revenue
- FONR $104,351,318.00
- ZNTL $26,865,000.00
- Revenue This Year
- FONR N/A
- ZNTL N/A
- Revenue Next Year
- FONR N/A
- ZNTL N/A
- P/E Ratio
- FONR $12.77
- ZNTL N/A
- Revenue Growth
- FONR 1.43
- ZNTL N/A
- 52 Week Low
- FONR $12.00
- ZNTL $1.01
- 52 Week High
- FONR $17.98
- ZNTL $4.46
- Technical
- Relative Strength Index (RSI)
- FONR 43.73
- ZNTL 43.96
- Support Level
- FONR $15.19
- ZNTL $1.40
- Resistance Level
- FONR $15.79
- ZNTL $1.50
- Average True Range (ATR)
- FONR 0.26
- ZNTL 0.11
- MACD
- FONR -0.03
- ZNTL -0.04
- Stochastic Oscillator
- FONR 18.99
- ZNTL 17.86
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.